Comments on:

FDA panel backs drug for early stage breast cancer

Back to the article » |
WASHINGTON (AP) — A biotech drug from Roche moved one step closer Thursday to becoming the first medicine approved to treat breast cancer before surgery. The Food and Drug Administration's panel of cancer experts voted 13-0, with one abstention, that the benefits of Perjeta as an initial treatment for breast cancer outweigh its risks. The recommendation is not binding, but sets the stage for...

To learn more about commenting on and our community guidelines, please see our comments FAQ.